Literature DB >> 27614501

[Radiotherapy for soft tissue sarcomas: Technical evolution and impact on clinical benefit].

C Llacer-Moscardo1, C Bourgier2, A Morel2, P Fenoglietto2, S Carrère3, N Firmin4, D Azria2.   

Abstract

The standard treatment for extremity soft tissue sarcomas is based on the association of surgery and radiotherapy. This strategy allows local control improvement with the risk of increased toxicity. There is therefore a growing interest to identify those patients who will benefit from radiotherapy and those who will have the same local control with surgery alone. Furthermore, the development of toxicity has been correlated with the extension of the irradiated volume and the volume receiving high doses. Technological development as intensity modulated radiotherapy and image-guided radiotherapy allows limited irradiated volume improving the protection of the organs at risk leading to clinical benefit improvement. Moreover, efforts are being done to improve local control for the patients at high risk of local relapse. In this paper, we discuss all these mentioned aspects.
Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Contrôle local; IMRT; Local control; RCMI; Sarcomes des tissus mous; Soft tissue sarcoma; Toxicity; Toxicité

Mesh:

Year:  2016        PMID: 27614501     DOI: 10.1016/j.canrad.2016.07.074

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

1.  A matched cohort study of radio-chemotherapy versus radiotherapy alone in soft tissue sarcoma patients.

Authors:  Daniela Greto; Mauro Loi; Francesca Terziani; Luca Visani; Pietro Garlatti; Monica Lo Russo; Ausilia Teriaca; Cristina Muntoni; Camilla Delli Paoli; Juliana Topulli; Domenico Campanacci; Giovanni Beltrami; Guido Scoccianti; Pierluigi Bonomo; Isacco Desideri; Giulio Francolini; Lorenzo Livi
Journal:  Radiol Med       Date:  2018-09-12       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.